Abstract: A method of treating a neurodegenerative disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a CXCR4 antagonist and lactate or/and zinc. Kits for treating same are also disclosed.

Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.

Abstract: The invention relates to a filamentous bacteriophage, carrying bacterial Lipopolysaccharide (LPS) endotoxin on its surface, for use in treating cancer and in inhibiting angiogenesis, and in a different context, for use in promoting angiogenesis in diseases or conditions in which there is insufficient angiogenesis.

Abstract: The present invention provides use of an inhibitor of G protein-coupled receptor CXCR4 for treating amyotrophic lateral sclerosis (ALS), for inhibiting glutamate release in astrocytes, or for increasing remyelinization in motor neurons.

Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.

Abstract: The invention relates to a filamentous bacteriophage, carrying bacterial Lipopolysaccharide (LPS) endotoxin on its surface, for use in treating cancer and in inhibiting angiogenesis, and in a different context, for use in promoting angiogenesis in diseases or conditions in which there is insufficient angiogenesis.

Abstract: The present invention is directed to a filamentous bacteriophage for use in treating a neurodegenerative tauopathy or susceptibility to a neurodegenerative tauopathy and a method of using the bacteriophage for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein, such as in a patient suffering from neurodegenerative tauopathy. The filamentous bacteriophage used in the present invention does not display (i) a mammalian cell internalization signal (ii) a ?-amyloid antigen or an antibody to ?-amyloid, or (iii) a tau protein antigen or an antibody to tau protein.

Abstract: The present invention is directed to a filamentous bacteriophage for use in treating a neurodegenerative tauopathy or susceptibility to a neurodegenerative tauopathy and a method of using the bacteriophage for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein, such as in a patient suffering from neurodegenerative tauopathy. The filamentous bacteriophage used in the present invention does not display (i) a mammalian cell internalization signal (ii) a ?-amyloid antigen or an antibody to ?-amyloid, or (iii) a tau protein antigen or an antibody to tau protein.

Abstract: The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an A?PP epitope spanning the ?-secretase cleavage site of A?PP and a method for inducing an immune response against the ?-secretase cleavage site of A?PP using this immunizing composition. The present invention is also directed to antibodies against the ?-secretase cleavage site of A?PP and their use in a method for inhibiting the formation of amyloid ?.

Abstract: Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.

Abstract: Anti-A?P scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of A?p 1-40 and disaggregate A?p 1-40 fibrils generated in vitro. The anti-A?p scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-A?P scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.

Abstract: Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.

Abstract: Anti-A?P scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of A?p 1-40 and disaggregate A?p 1-40 fibrils generated in vitro. The anti-A?p scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-A?P scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.

Abstract: Anti-A?P scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Abp 1-40 and disaggregate Abp 1-40 fibrils generated in vitro. The anti-A?p scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-A?P scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.

Abstract: The present invention relates to the use of a filamentous bacteriophage, which displays an antibody that specifically binds to a pro-inflammatory cytokine, either alone or in combination with a filamentous bacteriophage that does not display a mammalian cell internalization signal, to treat Parkinson's disease.

Abstract: Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.

Abstract: Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.

Abstract: The present invention relates to the use of a filamentous agent other than a filamentous bacteriophage to disaggregate aggregated proteins in plaque or to treat a patient suffering from or susceptible to a disease characterized by the presence of plaque.

Abstract: Unglycosylated anti-amyloid antibodies maintained all the antigen recognition functions of the native glycosylated anti-amyloid antibodies but without, or with a much reduced, property of triggering Fc receptor-mediated inflammation response in the brain. Such unglycosylated antibodies can be used in a method for preventing, inhibiting, or treating a disease or disorder characterized by amyloid aggregation with a diminished risk of triggering or exacerbating neuroinflammation.

Abstract: Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.